The FDA will limit the vaccine’s availability later this year to older adults and those who may be at risk of severe illness.

CAMBRIDGE, MA / ACCESS Newswire / May 23, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that it has submitted an ...

Almost immediately after former US president Joe Biden's office announced he had been diagnosed with an aggressive prostate ...

The U.S. Food and Drug Administration approved Novavax's COVID-19 vaccine with age restrictions after a six-week delay.

The Food and Drug Administration has granted full approval to Novavax, Inc. (NASDAQ:NVAX) COVID-19 vaccine, but with notable ...

See what infectious disease doctors have to say as government officials appear poised to scale back COVID vaccines and the ...

The U.S. FDA has approved Novavax's COVID-19 vaccine, Nuvaxovid, for older adults and those aged 12 to 64 at risk of severe illness. Despite missed deadlines and regulatory challenges, the approval is ...

Federal health agencies were alerted in February 2021 to "large reports of myocarditis" in young people who received the ...

While the clearance is only for use in certain groups, Novavax’s long-awaited OK is still seen by analysts as a “win” for the ...